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1. Introduction 
Ulcerative colitis (UC) is a chronic inflammatory disease that primarily affects the colonic 
mucosa; it is most commonly diagnosed in patients aged 15-35 years, although the condition 
can affect patients of any age and of either sex. It's exact etiologie remain uncertain. The 
annual incidence of ulcerative colitis in western countries is estimated to be 6-8 cases per 
100,000 individuals, with the prevalence reaching 70-150 cases per 100,000 individuals. The 
disease course is generally relapsing-remitting, with patients experiencing few or no 
gastrointestinal symptoms between symptomatic relapses.  
As medical options increase, decisions about the sequence and timing of therapy and 
surgery in particular become more difficult. Consequently a therapeutic strategy is 
necessary, keeping an eye on the direction of travel to avoid going round in circles from one 
incompletely effective therapy to another. Patients live with a considerable symptom burden 
despite medical treatment in the hope that a cure for ulcerative colitis will emerge. This 
article reviews the new advances in ulcerative colitis, epidemiology, pathogenesis, 
diagnosis, new therapeutic goals, as well as therapy that occurred in the past year. 
2. Epidemiology  
The prevalence of ulcerative colitis (UC) rapidly increased in western countries in the 
second half of the twentieth century and is becoming more common in the rest of the world 
as different countries adopt a Western lifestyle.(1) There are many similarities between Asian 
and Western populations, even significant differences do exist. These differences in genetic 
and environmental influences represent an important opportunity to understand the 
influences that lead to the development UC. (2) UC tends to be a disease of young 
adulthood.(3) There are slightly more women affected than men. Cigarette smoking 
protective in ulcerative colitis, an effect that has yet to be satisfactorily explained. It is well 
known that smoking reduces the severity of disease in ulcerative colitis, reducing the 
number of hospitalizations and need for steroids or surgery. By contrast, smoking increases 
the severity of Crohn's disease, increasing the number of exacerbations and the need for 
steroids.(4) Additionally, early appendectomy (before age 20) has resulted in a lower risk of 
ulcerative colitis.(5,6) Accurate descriptive epidemiology is needed now more than ever, so 
that it can be applied to the various populations with inflammatory bowel disease (IBD) 
such that further genetic and clinical studies can be conducted. 
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3. Genetics in ulcerative colitis 
It is well known that IBD is a disease that has appeared over the last century and that its 
incidence varies markedly with geographic location, urbanization, and industrial 
development. Such data clearly highlight the presumptive importance of environmental 
factors in modulating disease evolution in IBD. However, a variety of other epidemiologic 
data also highlight the intimate role played by genetic factors in IBD pathogenesis. For 
instance, marked ethnic and racial differences in disease prevalence have been noted, 
particularly in Ashkenazi Jews. Furthermore, twin studies have demonstrated a much 
higher rate of disease concordance in monozygotic compared with dizygotic twins, 
particularly in Crohn's disease. However, it should also be highlighted that over 60% of 
monozygotic twins are not concordant for IBD. Thus, genetic susceptibility alone, while 
important, is clearly not sufficient for the development of disease. 
The greatest identifiable risk factor for the development of IBD is having a first-degree 
family member affected by the disease. Affected first-degree relatives are more frequently 
identified in patients with Crohn's disease (9% to 15%) than in those with ulcerative colitis 
(6% to 9%), and appear to be more common in patients with earlier disease onset and in 
those of Jewish descent. Siblings of an affected individual are at highest risk. The risk of 
disease in the offspring of patients is very difficult to calculate accurately due to the paucity 
of data. Offspring of couples who are both affected by IBD (either Crohn's disease, 
ulcerative colitis, or "mixed" [ie, 1 parent with Crohn's disease and the other with ulcerative 
colitis]) appear to have about a 30% chance of developing disease by 30 years of age. If only 
a single parent has IBD, then the risk appears to be much less: approximately 9% if the 
parent has Crohn's disease, and about 6% if the parent has ulcerative colitis. 
The substantial heterogeneity seen in IBD suggests that it does not encompass only 2, but 
many inflammatory disorders. Various epidemiologic data support this concept. Multiply-
affected families show surprising concordance for disease phenotype, including age of 
onset, disease location, and extra-intestinal manifestations. Longitudinal studies examining 
changes in Crohn's disease phenotype over time demonstrate the stability of disease 
location, but the progression of disease behavior following diagnosis. The current genetic 
model for IBD attempts to encompass these observations. It is generally believed that there 
may be a number of "susceptibility genes" that confer a general predisposition to IBD. Other 
"modifier genes," although they don't initiate disease, then act to influence specific 
phenotypic characteristics such as disease behavior, complications, and treatment response, 
among others. Both "susceptibility" and "modification" may be further influenced by 
interaction with environmental factors.  
4. Mechanisms of disease and pathogenesis 
Chronic intestinal inflammation in UC results from the interactions of genetic, immunologic, 
microbial and environmental factors.(7)  It is proposed that IBD results from the failure to 
appropriately downregulate nonspecific inflammation initiated by an environmental trigger, 
such as an acute, self-limited infection or NSAID use. (8) Normal hosts quickly clear 
infections of invasive enteric bacteria, downregulate innate immune responses and heal the 
injured mucosa without stimulating effector T-cell responses. (9) By contrast, genetically 
susceptible hosts who are unable to clear an invading pathogen and/or generate tolerogenic 
immune response to commensal microbial agents—by mounting appropriate innate 
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immunity, downregulating immune responses or healing the mucosal barrier—
subsequently activate pathogenic T-cell responses to commensal bacteria and proceed to 
chronic, relapsing intestinal inflammation. Resistance to T-cell apoptosis, lack of response to 
downregulatory signals and continuous exposure to luminal antigens and adjuvants help 
sustain this inflammatory response.(10) 
Many environmental factors can influence mucosal immune responses and enteric bacteria 
composition, including diet, smoking, stress, altered microenvironment and NSAID 
exposure. (11) Although It postulated that self-limited, nonspecific infections can initiate the 
onset of chronic inflammation and reactivate quiescent disease, it is possible that a persistent 
pathogen could cause disease in individuals unable to clear infections, or that the 
commensal bacteria of some patients could acquire virulence factors (e.g. toxins, adherence 
and/or invasion properties) that might cause chronic intestinal inflammation.(12)  
5. Diagnosis of ulcerative colitis 
Endoscopy; Colonoscopy is more sensitive than radiographic studies in detecting early 
changes associated with UC, and represents the primary modality to obtain tissue for 
histologic evaluation. Clinicians should be cognizant that even if the colonic mucosa appears 
macroscopically normal, there may be histologic changes diagnostic of UC. Therefore, it is of 
paramount importance that biopsies be procured, even from tissue that appears 
endoscopically normal. Histology represents the most sensitive measure of disease extent 
and activity. In 10% of all patients, colonoscopy with biopsy is unable to differentiate 
between Crohn's colitis and ulcerative colitis. (13)  
In early-stage edema, confluent erythema with rectal involvement is typical. As the disease 
progresses, granularity and contact bleeding is appreciated endoscopically. With 
progression of disease to the late stages, discrete ulcerations with pus/exudate and loss of 
haustral folds is characteristic. The presence of aphthoid ulcerations is not seen in patients 
with ulcerative colitis. Chronic inflammation frequently leads to diffuse mucosal atrophy, 
leaving behind hypertrophic areas of swollen, edematous tissue and areas of granulation 
that assume a polypoid configuration. These areas, known as pseudopolyps, have no 
malignant potential and occur in both ulcerative colitis and Crohn's disease. (14) 
Histologically, ulcerative colitis has alterations of crypt architecture including crypt 
architectural distortion. Paneth cells are commonly found in normal individuals, proximal 
to the hepatic flexure; however, in patients with ulcerative colitis, it is not uncommon to 
discern their presence distal to the hepatic flexure suggestive of prior crypt destruction and 
subsequent regeneration. It is most common to find these features distally. It is also common 
to find basal plasma cells and many basal lymphoid cells, indicating the presence of 
chronicity. (19) Basal plasma cells are, however, not specific for ulcerative colitis and may be 
seen in other chronic disorders, such as collagenous colitis and Crohn's disease and, rarely, 
in infectious colitis. Other minor features of ulcerative colitis include hyperplasia of 
argentaffin cells, mucosal vascular congestion with edema, and focal hemorrhage. Depletion 
of goblet cell mucin is a characteristic and consistent finding in acute ulcerative colitis, and 
except where dysplasia is present, is another reliable indicator of disease activity. (15) 
Radiographic Studies; Radiographic imaging for evaluation of patients with ulcerative 
colitis also remains a standard and helps to differentiate ulcerative colitis from Crohn's 
disease. The presence of mucosal granularity is the earliest radiographically detectable 
evidence of disease in ulcerative colitis. The granular pattern is thought to result from 
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abnormalities associated with edema and hyperemia. (16) Early ulcer formation in ulcerative 
colitis appears as fine speckled barium collections superimposed on a granular-appearing 
mucosa. Other associated findings may be present, including haustral fold thickening, 
colonic shortening, polyps and pseudopolyps, strictures, dysplasia, colorectal cancer, and 
toxic dilation for various disease stages. (17) 
Serologic Testing; Combined serologic testing has also been proposed to help differentiate 
between ulcerative colitis and Crohn's disease in cases of indeterminate colitis. At this time, 
there is insufficient evidence to demonstrate that perinuclear anti-neutrophilic cytoplasmic 
antibody (pANCA) and anti-Saccharomyces cerevisiae antibody (ASCA) testing alone is 
completely reliable in reaching a definitive diagnosis.(18) The presence of ANCA, pANCA, 
ASCA, anti-OmpC (outer membrane porin from Escherichia coli), and anti-CBir1 (anti-CBir1 
flagellin) markers appears to be associated with ulcerative colitis and Crohn's disease.(19,20) 
More markers and combined serologic testing represent a promising step forward for 
diagnosis.  
6. Backwash Ileitis in ulcerative colitis 
Involvement of the distal ileum in ulcerative colitis (UC) is termed backwash ileitis (BWI). 
Most authors agree that BWI has a similar morphologic pattern of mucosal inflammation 
and injury to UC and does not have the features typical of CD. (21) Features that favor a 
diagnosis of CD rather than chronic UC with BWI, are an extensive length of involved small 
bowel, involvement of the jejunum, proximally located regions of active ileitis separated by 
skip regions of uninvolved cecum or distal ileum, greater inflammatory activity and 
mucosal injury in the ileum than the cecum, transmural ileal inflammation with granulomas 
and neural hyperplasia, and mucous gland (so-called pyloric gland) metaplasia of the ileal 
mucosa. (22) In endoscopic biopsy specimens, features that suggest a diagnosis of CD include 
mucous gland metaplasia or the constellation of focal lamina propria edema with crypt 
disarray and no to mild active inflammation that involves a small region of a tissue 
fragment surrounded by normal small bowel mucosa. Mild BWI consists of active 
inflammation and edema that is located predominantly in villus tips without significant 
lamina propria focal edema or crypt disarray. In BWI, mild ileal mucosal injury is found in 
association with moderate or markedly active cecal colitis. Focal ileal erosions with mild 
active inflammation seen in association with mildly active cecal colitis should be considered 
CD. (23) 
7. Indeterminate colitis 
Although some patients who are initially labelled as having indeterminate colitis eventually 
have classic features of ulcerative colitis or Crohn's disease, others who remain 
indeterminate may have a unique phenotype. If a unique phenotype exists, novel diagnostic 
tests are needed to positively identify this group, instead of relying on current tests that can 
only exclude ulcerative colitis and Crohn's disease. Until indeterminate colitis becomes a 
diagnosis based on positive test results, data regarding the epidemiology, response to 
therapy and cancer risk will likely remain difficult to interpret.(24,25) At present time 
serological tests can not diagnose or predict the course of indeterminate colitis. The 
serological tests would not be diagnostic for indeterminate colitis until there exists at least 
one test that positively identifies the subgroup of indeterminate colitis. (26) 
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8. Treatment of ulcerative colitis 
Clinical trials on ulcerative colitis have all used different endpoints to define response and 
remission. Some outcomes that matter to patients, such as hospitalization, time off work, 
surgery and mortality, are difficult to measure, but are only now being captured in large 
trials. Other outcomes (steroid-free remission, speed of response, time to relapse) also matter 
to patients, are readily understood, easily measured and more informative than composite 
indices. Surrogate markers for determining improved outcomes, such as fewer hospital 
visits, or surgery, include mucosal healing.  
9. 5-Aminosalicylic Acid (5-ASA) 
When free 5-ASA is administered orally, it is nearly completely systemically absorbed from 
the proximal small intestine and then extensively metabolized to N-acetyl-5-ASA in 
intestinal epithelial cells and the liver; it is then excreted in the urine. (27) 5-ASA has been 
shown to have a topical mechanism of action in the treatment of ulcerative colitis.(28) 
Therefore, strategies to "protect" orally administered 5-ASA from absorption until it reaches 
the colon have been developed. These strategies include the use of prodrugs; delayed-
release formulations; controlled-release formulations; and, more recently, sophisticated 
formulations that combine both delayed-release and sustained-release mechanisms. 
Prodrug Formulations; The first strategy employed to protect 5-ASA until it reaches the 
colon was to design prodrugs that release active drug in the colon by the bacterial enzyme 
azo reductase. Three such drugs were developed: sulfasalazine, olsalazine, and balsalazide. 
The oldest of these agents, sulfasalazine, consists of 5-ASA linked to sulfapyridine by an azo 
bond. Olsalazine comprises 2 molecules of 5-ASA linked by an azo bond as a dimer, and 
balsalazide consists of 5-ASA linked by an azo bond to 4-amino-benzoyl-beta-alanine. 
Sulfasalazine is formulated as a 500-mg tablet containing 200 mg of 5-ASA. Sulfasalazine is 
administered orally 4 times daily to minimize side effects associated with the sulfapyridine 
moiety. Olsalazine is formulated as a 250-mg capsule and is administered orally twice daily. 
Balsalazide is formulated as a 750-mg tablet that contains 262 mg of 5-ASA. Balsalazide is 
administered orally 3 times daily. A capsule formulation of balsalazide is currently under 
development. (29) 
Delayed-Release Formulations; The second strategy employed to protect 5-ASA until it 
reaches the colon was to coat the drug with polymers that release at pH 6 or pH 7, thus 
delaying release of active drug until it reaches the small bowel or the cecum. Four such oral 
drugs were developed: Asacol (Ohio), Salofalk (Germany), Mesasal (Canada), and Claversal 
(Germany). Asacol is a delayed-release tablet formulation of 5-ASA that is coated with a 
polymer called Eudragit-S, which releases drug in the terminal ileum and colon at pH ≥ 7.0. 
Salofalk, Mesasal, and Claversal are delayed-release tablet formulations that are coated with 
a polymer called Eudragit-L, which releases drug in the distal jejunum and proximal ileum. 
Asacol is formulated as a 400-mg tablet and as an investigational 800-mg tablet (currently 
available only in Canada); it is administered orally 2-3 times daily. Salofalk, Mesasal, and 
Claversal are formulated as 250- and 500-mg tablets and are administered orally 3-4 times 
daily. (30) 
Controlled-Release Formulations; The third strategy employed to protect 5-ASA until it 
reaches the colon was to formulate the 5-ASA as ethylcellulose-coated microgranules that 
gradually release beginning in the duodenum and continuing throughout the jejunum, the 
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ileum, and the colon to the rectum. (31) Only 1 controlled-release drug was developed: 
Pentasa (Pennsylvania). After the ethylcellulose-coated microgranules release the drug 
throughout the small intestine and colon.[ (32) Pentasa is formulated as 250-mg and 500-mg 
tablets, 250-mg and 500-mg capsules, and 1000-mg sachets; this agent is administered orally 
1 g once or twice daily for induction of remission and treatment of mild-to-moderate active 
ulcerative colitis. 
Delayed- and Sustained-Release Formulations; The fourth strategy employed to protect 5-
ASA until it reaches the colon was the use of a sophisticated formulation that coats pellets or 
matrices containing 5-ASA with polymers that release at pH 6 or pH 7, thus delaying release 
of pellets or matrices until they reach the small bowel or the cecum. The pellets or matrices 
contain 5-ASA that gradually releases, beginning in the distal small bowel and continuing 
throughout the colon to the rectum. Two such drugs have been developed: mesalamine 
pellets (Salofalk GranuStix; Germany) and mesalamine with MMX technology (Lialda in the 
United States and as Mezavant in Europe).  
Mesalamine pellets have an outer coating of the Eudragit-L polymer and an additional 
retarding polymer in the pellet core. The entire mesalamine pellet dose passes unaltered to 
the distal jejunum and proximal ileum. After the Eudragit-L polymer disintegrates at pH 6.0 
in the distal jejunum and proximal ileum and the 5-ASA is then released from the pellet 
core. (33) Mesalamine pellets are formulated as 500-mg sachets and are administered orally 1-
3 times daily. 
MMX technology has a pH-sensitive film which delays the release of 5-ASA until the tablet 
reaches the terminal ileum. Intestinal fluids are thought to interact with hydrophilic 
excipients causing the tablet to form a viscous gel, which slows diffusion of 5-ASA into the 
colonic lumen. It is supposed that other lipophilic excipients reduce the rate of dissolution 
and extend the process of delivery of 5-ASA. It is clear that it works, for both inducing and 
maintaining remission in single or twice daily doses. (34-36)  
Once-daily mesalamine 
Once-daily oral formulations of 5-aminosalicylic acid (5-ASA) are likely to be preferred if 
they offer comparable efficacy and improved adherence. This premise appears correct with 
Pentasa showed a better remission rate at 1 year in the single daily dose group. 
Questionnaires confirmed significantly greater compliance and acceptability in the once-
daily group. Same results with mesalamine MMX and Salofalk (37,38) the effect is likely to be 
generic rather than compound specific. 
High-dose 5-aminosalicylic acid 
The benefit of mesalamine 4.8 over 2.4 g/day is limited to symptom improvement rather 
than remission in mild or moderately active colitis, as confirmed in the large ASCEND I trial 
and a systematic review. (39,40) 
Induction and maintenance of remission with 5-aminosalicylic acid therapy 
The efficacy of oral and rectal formulations of 5-aminosalicylate acid (5-ASA) has been 
demonstrated in clinical trials as both induction and maintenance agents for mildly to 
moderately active ulcerative colitis. Two large meta-analyses showed that 5-ASAs were 
significantly more effective than placebo for induction of remission, and within the limits of 
this analysis, there was no significant difference between the efficacy of sulfasalazine and 
the other 5-ASA therapies. (41)  
www.intechopen.com
 
Ulcerative Colitis 
 
173 
At present, there are no published maintenance-of-remission studies involving mesalamine 
pellets or MMX mesalamine in patients with active ulcerative colitis. 
As with other chronic diseases requiring maintenance therapy, compliance with the 
prescribed medical regimen is a challenge. Although compliance in clinical trials, which 
involve a highly selected and motivated patient group, is greater than 80%, much lower 
rates were seen in community-based, "real-world" studies (40% to 60%).(42) Noncompliance 
results in an increased risk for disease relapse, a diminished quality of life, and a possible 
increase in the risk for colorectal cancer. (43) Therefore, successful management of patients 
with ulcerative colitis requires treatment strategies that encourage and confirm compliance 
with the prescribed therapeutic plan.  
10. Combination oral and topical 5-ASA therapy 
A fundamental principle of 5-ASA therapy is delivery of the drug to the site of disease. 
Several studies, including a meta-analysis, confirmed the efficacy of 5-ASA in an enema 
formulation in both inducing and maintaining remission in left-sided ulcerative colitis 
(defined as distal to the splenic flexure). (44,45) The addition of topical 5-ASA to oral therapy 
increases mucosal levels of mesalamine by 3-fold in the descending colon and over 20-fold 
in the rectum.(51) Moreover, it has been demonstrated repeatedly that the combination of 5-
ASA in oral and enema formulations is superior to either therapy alone in inducing and 
maintaining remission of extensive colitis. (46)  
11. Corticosteroids 
Systemic corticosteroids are often given to ulcerative colitis patients with moderately to 
severely active disease. Over 5 years study, those patients who had achieved complete 
response with steroid treatment had less need for immunosuppression, fewer 
hospitalizations, and a longer time interval to relapse in comparison with the group not 
received steroids. However, colectomy rates were similar among all patient groups. 
Therefore, the study authors suggested that more aggressive therapy, probably with 
immunosuppressants, is required for patients who do not completely respond to their first 
corticosteroid course. (47)  
The impact of prednisone on bone density, independent of disease activity, has been the 
subject of debate, as clinicians have reported osteoporosis in corticosteroid-naive UC 
patients, and found normal bone densities in some patients on long-term steroids. 
The most serious complication associated with corticosteroid therapy in UC is avascular 
necrosis (osteonecrosis). A search of a large database identified 94 patients with IBD and 
avascular necrosis; these subjects were matched to IBD controls without avascular necrosis. 
Important to note was that 6 patients with avascular necrosis had never been exposed to 
corticosteroids. Likely risk factors for avascular necrosis included systemic steroid exposure, 
IBD severity, parenteral nutrition, estrogen exposure, and cigarette smoking in ulcerative 
colitis patients. Although some of these risk factors are modifiable, above all, corticosteroid 
therapy must be minimized in IBD patients. (48,49) 
Dexamethasone encapsulated into the patient's own erythrocytes and infused back into the 
patient may offer a way to deliver adequate steroid therapy to tissues while minimizing the 
adverse effects often associated with steroid use. Autologous erythrocytes can be used as 
drug carriers, owing to the capability of their membrane to be opened and resealed in 
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appropriate conditions. An ideal drug to be encapsulated into erythrocytes is 
dexamethasone 21-phosphate (Dex 21-P), a biologically inactive compound. In this 
randomized clinical trial involving 40 patients with mildly to moderately active ulcerative 
colitis, subjects received either dexamethasone encapsulated into erythrocytes at entry and 
at day 14; prednisolone 0.5 mg/kg with tapering; or sham infusions of dexamethasone 
encapsulated into erythrocytes. At 8 weeks, remission was achieved in 85% of patients who 
received the erythrocyte-mediated delivery of dexamethasone, in 80% of prednisolone-
treated patients, and in 20% of sham-treated patients (P < .01). No patient treated with 
encapsulated dexamethasone experienced steroid-related side effects, as compared with 
80% of the prednisolone-treated group. The study authors concluded that very low doses of 
dexamethasone delivered via encapsulated erythrocytes may be as effective as prednisolone 
but without the steroid-related side effects. (50,51) 
Steroid resistance remains a major clinical challenge, but emerging knowledge of the 
pathogenesis of IBD is enabling the development of new agents to overcome this resistance. 
Many difficult questions remain to be answered, such as whether steroid resistance is an 
inherent property of an individual or if it is acquired. The demonstration of steroid 
resistance in the lymphocytes of healthy individuals would suggest that it is an inherent 
property of an individual that is only of relevance in the presence of inflammatory 
disease.(52) However, the observation that some individuals become less responsive to 
steroids over time makes this hypothesis more difficult to support. The clonal nature of 
lymphocyte proliferation raises the possibility that steroid treatment gradually depletes 
activated steroid-sensitive lymphocytes leaving behind a highly steroid-resistant population 
over time. May be, combination treatment with existing treatments, such as is employed in 
the treatment of TB or even malignancy will offer the answer to preventing the development 
of steroid-resistant lymphocyte clones. Steroid-resistant UC remains a difficult condition to 
treat. We must consider when designing future trials whether response to treatment is an 
adequate end point. Patients need to be in steroid-free remission, and this is what we should 
aspire to achieve. (53) 
12. Azathioprine/6-Mercaptopurine 
Thiopurines are widely used in the treatment of inflammatory bowel disease (IBD). 
However, in clinical practice, azathioprine (AZA) or mercaptopurine (MP) are not effective 
in one-third of patients and up to one-fifth of patients discontinues thiopurine therapy 
because of adverse events. (54) Dosing recommendations for the thiopurine analogs have 
traditionally been based on the patient's weight and the impact on hematologic and hepatic 
parameters. More recently, measurement of the levels of the 2 primary metabolites, 6-
thioguanine (6-TGN; thought to be a marker of drug efficacy), and 6-methylmercaptopurine 
(6-MMP; associated with hepatotoxicity in some instances), as well as the activity of the 
thiopurine methyltransferase (TPMT) enzyme, has been purported to provide a more 
accurate prediction of patient response to therapy and of appropriate dosing. (55) 
In patients refractory to thiopurines who have high TPMT activity and preferentially 
metabolize the agents to produce the 6-MMP metabolite instead of the 6-TGN metabolite. 
The addition of low-dose allopurinol (100 mg or less daily) along with a greatly reduced 
dose of the purine analog (often 25-50 mg) not only resulted in treatment success, but also in 
a reversal of the 6-TGN:6-MMP nucleotide ratio to favor production of the 6-TGN 
nucleotide. The 6-mercaptopurine dose ranged from 0.35 mg/kg to 0.61 mg/kg, although 
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the study authors suggested lowering the dose to 25 mg daily for 4 weeks prior to initiating 
the allopurinol. Due to the risk for serious hematologic consequences, further research 
recommended be done prior to the adoption of this combination of therapies in clinical 
practice. (56) 
Intolerance to 6-mercaptopurine does not necessarily mean that the same patient will be 
unable to be treated with azathioprine, although severe hematologic reactions and 
pancreatitis resulting from treatment with one of the agents usually precludes challenge 
with the other. A previous study suggested that patients with an intolerance to azathioprine 
could subsequently receive 6-mercaptopurine. (57) A practical option for patients who cannot 
tolerate thiopurines (both azathioprine and 6-mercaptopurine) is to try mycophenolate 
mofetil. In a case series of 70 patients, 24% achieved steroid-free remission for almost 3 
years. (58) 
13. Calcineurin inhibitors (Cyclosporine/Tacrolimus) 
Clinical improvement usually occur within 1-4 weeks of treatment with calcineurin 
inhibitors and duration of therapy is 3-6 months. (59) 
Cyclosporine has demonstrated efficacy in the treatment of severe steroid-refractory 
ulcerative colitis, but questions persist as to the long-term outcomes of those patients treated 
with the "salvage" agent. In a study of 75 patients, 79% avoided colectomy during their 
hospitalization; 56% were well at 6 months; and 45% were still well at a mean of 14.7 years 
later. Higher rates were seen among the 69 patients in the latter subset, with 80% initially 
avoiding colectomy, 73% well at 6 months, and 54% still well at a mean of 8.6 years later. (60-
62) 
Tacrolimus showed better results than cyclosporine as it has powerful immunosuppressant, 
10 to 20 times greater than cyclosporine and it has consistent absorption even in the 
presence of gastrointestinal disease. Its intravenous dose 0.01-0.02 mg/kg/day and 0.1-
0.2mg/kg/day orally. (63)  
Prophylaxis against Pneumocystis carinii pneumonia is strongly recommended when using 
the calcineurin inhibitors. (64) 
14. Anti-tumour necrosis factor therapy for ulcerative colitis 
Infliximab therapy for ulcerative colitis showed modest steroid-free remission rate (21% at 6 
months in the combined active ulcerative colitis trials ACT 1 and ACT 2). Nevertheless, 
subsequent analysis showed an associated reduction in colectomy,(65)  but whether this 
benefit is maintained remains unclear. Outside of clinical trial settings, outpatient case series 
have reported colectomy rates of up to 50% after a median follow up of 13 months, (66) but 
lower rates in less refractory patients. Older patients and those who are perinuclear 
antineutrophil cytoplasmic antibody (p-ANCA) positive may respond less well.(67) A single 
series of 10 patients with ulcerative colitis who had lost response to infliximab were given 
adalimumab (160/80) in a 4-week open-label trial. Four patients improved, six did not 
respond, and of these, two went onto colectomy. (68) Phase III studies of adalimumab for 
ulcerative colitis are in progress. Infliximab for acute severe colitis is best considered 
separately, as is the question of whether to continue immunomodulators. The "real-world" 
experience with infliximab in ulcerative colitis seems to recapitulate efficacy results seen in 
the large clinical trials. (69) 
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15. Long-lasting clinical remission in patients with ulcerative colitis 
The induction of an effective and long-lasting clinical remission, including tissue mucosal 
healing, is of the utmost importance in reducing the need for surgery and in lessening the 
incidence of dysplasia and cancer. Maintenance therapy should begin only after a patient 
has achieved a favorable clinical response to induction therapy. (70) 
The US FDA has set the stage in adopting stringent criteria for clinical remission, including 
tissue healing with symptomatic improvement, for future clinical trials investigating the 
efficacy of medical therapies in patients with ulcerative colitis. This renewed 
standardization of controlled clinical trials will lead to the development of more effective 
therapies that improve patient outcome while potentially avoiding complications of long-
standing ulcerative colitis. (71) 
16. Acute severe ulcerative colitis 
Intravenous corticosteroids remain the mainstay for acute severe colitis. In case of steroid 
refractory severe ulcerative colitis, the choice for rescue therapy in 2008 is between 
infliximab and calcineurin inhibitors (cyclosporine A or tacrolimus).(72) Controlled trials are 
needed, because case series report 20-75% coming to colectomy after infliximab for 
intravenous-steroid resistant ulcerative colitis.(73) Safety is a key factor, especially if surgery 
becomes necessary. While it is generally accepted that elective surgery in the presence of 
infliximab is safe, the same may not apply to emergency colectomy for acute severe colitis. 
Combination therapy in an attempt to avoid colectomy cannot be recommended. (74) The 
message should be to use objective indices that predict outcome at an early stage (on the 
third day of intravenous steroid treatment). A new index for patients with acute severe 
colitis has been developed and validated which depend on C-reactive protein and stool 
frequency. (75)  
17. Surgery for ulcerative 
Colectomy is an integral component of an overall therapeutic strategy. Patients with an ileal 
pouch anal anastomosis (IPAA) have a quality of life similar to patients with ulcerative 
colitis in remission or mild disease, although it depends on the measure used. (76) 
Complications of IPAA have been reviewed, but a common dilemma is the impact of pelvic 
surgery on fecundity and pregnancy on pouch function. Infertility rate was 12% before and 
26% after IPAA among 945 patients in seven studies. No significant difference was seen in 
pouch function after vaginal delivery, but elective caesarean section for patients with a 
pouch tends to be favoured after discussion with the obstetrician and patient. (77) 
18. Pouchitis 
Pouchitis, a non-specific, idiopathic inflammation of the ileal reservoir, has become the most 
frequent long-term complication following pouch surgery for UC. The reported incidence of 
pouchitis is largely variable because of differences in nature and duration of the follow-up 
and, particularly, because a myriad of diagnostic criteria have been used to define this 
syndrome. Most patients who develop acute pouchitis do so within the first year, but some 
may suffer their first attack some years following surgery. (78) 
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Metronidazole appears to be an effective therapy for active chronic pouchitis. Bismuth 
carbomer foam enemas may not be an effective therapy for chronic active pouchitis. Oral 
probiotic therapy with VSL - 3 appears to be an effective therapy for maintaining remission 
in patients with chronic pouchitis in remission. There is no evidence of a difference in the 
maintenance of symptomatic remission in patients with chronic pouchitis treated with 
glutamine versus butyrate suppositories, and it is unknown whether glutamine and 
butyrate are equally effective or ineffective. Additional randomized, double - blind, placebo 
- controlled, dose - ranging clinical trials are needed to determine the efficacy of empiric 
medical therapies currently being used in patients with pouchitis. (79-81) 
19. Novel therapies 
Although conventional therapy accounts for the management of at least 90% of patients 
with ulcerative colitis, it is often new treatment that attracts attention. Therapeutic targets 
other than tumour necrosis factor (TNF) are sorely needed, since conventional therapy, 
however well used, is reaching its limits.(82) 
Visilizumab; This anti-CD3 monoclonal antibody binding to activated T cells to induce 
apoptosis showed real promise as rescue therapy for intravenous steroid-resistant ulcerative 
colitis. The phase 1 dose-ranging study has been reported, but sadly the phase III study was 
suspended in 2007 when interim analysis showed no benefit.(83) 
Phosphodiesterase 4 Inhibitor; Phosphodiesterase 4 is a key enzyme in cell homeostasis and 
inflammation, and its inhibition has been useful in rheumatoid arthritis and other diseases. 
A phase II study of tetomilast (OPC-6535) in 186 patients with active ulcerative colitis 
showed potential benefit in those with more active disease, but did not reach significance for 
remission or overall response.(84) 
Phosphatidylcholine; Insufficient phosphatidylcholine in colonic mucus fits with current 
concepts of a primary defect in barrier function. Significantly more patients given 
phosphatidylcholine 2 g/day were able to stop steroids compared with placebo.(85)  
Other Agents; Interferon-β still seeks a role for treating ulcerative colitis, although a case 
report describes the onset of the condition during treatment with interferon-β for multiple 
sclerosis. A similar disparity applies to rituximab, an anti-CD20-antibody that might inhibit 
B-cell-mediated destruction of epithelial cells. It is undergoing pilot studies in ulcerative 
colitis, but a case report describes disease exacerbation. Abatacept prevents T-cell activation 
by inhibiting costimulation through CD28 and worked in two animal models of colitis; it is 
undergoing clinical trials at present. (86) 
20. IV Iron therapy for anaemia in ulcerative colitis 
In most studies testing oral iron, 100–200 mg of ferrous salts (fumarate or sulphate) were 
administered. As only small amounts of iron are absorbed (10–30 mg) the majority of 
ingested iron passes along within the bowel content. (87) At sites of ulcers, the iron-rich 
luminal matter may increase the formation of hydroxyl radicals (by catalysing the Fenton 
reaction: Fe2+ + H2O2 → Fe3+ + OH + OH-). The hydroxyl radical is the primary oxidizing 
species; it can be used to oxidize and break apart organic molecules and thereby may 
enhance tissue damage and disease activity of the underlying IBD. As this hypothesis is 
difficult to test in patients, it has been subject of several studies using animal model of IBD. 
(88) Many publications that tested the effect of iron on intestinal disease activity, oxidative 
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stress or the degree of mucosal inflammation in rodent models of IBD. Although the 
experimental setting, the iron dose and the readout are quite diverse, these studies 
unanimously support the hypothesis of iron-induced hydroxyl radical generation in the 
inflamed tissue leading to worsening of intestinal inflammation and increased colon 
carcinogenesis. (89) 
From eight studies that tested oral iron in IBD, intolerance was a common finding leading to 
discontinuation in up to 21%. Two studies using ferric iron reported fewer side effects 
despite good effectiveness. Some case–control studies saw similar intolerance to non-IBD 
patients in others the frequency and spectrum of side effects (increase in diarrhoea vs. 
constipation) was considerably different. A 15-year-old girl developed typical symptoms of 
UC after treatment of anaemia with ferrous sulphate. Recently, some worsening of 
proctosigmoiditis was demonstrated by rigid sigmoidoscoy. (90) 
Intravenous iron therapy for IBD-associated anaemia has been suggested in the 1970s, but 
clinical trials have not been performed until the early 1990s. Studies during the last 10 years 
showed that IV iron polymaltose or iron sucrose appear effective and safe. Iron sucrose may 
be administered undiluted as a 100 mg slow intravenous injection over 2 to 5 minutes or as 
an infusion of 100 mg, diluted in a maximum of 100 mL of 0.9% NaCl over a period of at 
least 15 minutes per session for a total cumulative dose of 1000 mg within the 14 day period. 
There is limited experience with administration of an infusion of 500 mg iron sucrose 
diluted in a maximum of 250 mL of 0.9% NaCl, over a period of 3.5 to 4 hours on day 1 and 
day 14. Hypotension may occurred in up to 10% of patients treated. 
Patients receiving regular parenteral iron therapy require monitoring of hematologic 
parameters and iron indices (Hb, Hct, transferrin saturation, and ferritin). 
Sufficient IV iron should be administered to maintain transferrin saturation between 20% 
and 50%. Iron therapy should be withheld in patients with transferrin saturation ≥50%. 
Since transferrin saturation values increase rapidly after IV administration of iron sucrose, 
serum iron values may be reliably obtained 48 hours after IV iron sucrose dosing. (91,92) 
21. Colorectal cancer in ulcerative colitis 
There is no doubt that patients with ulcerative colitis have an increased risk for colorectal 
cancer, and that colorectal cancer remains an important cause of death in IBD patients. It is 
interesting to note that worldwide, ulcerative colitis related colorectal cancer rates seem to 
be diminishing, possibly due to the benefits of cancer surveillance programs, 
chemopreventive efforts, or to a changing risk-factor profile. Cancer surveillance 
colonoscopy programs have been in place for IBD patients for at least 30 years. Perhaps the 
efforts of gastroenterologists have been successful in decreasing cancer rates over that time 
period. It is encouraging to see that many patients with advanced neoplasia (high-grade 
dysplasia or cancer) have had earlier examinations where low-grade dysplasia was detected. 
Inflammation appears to be an important biological risk factor for the development of CRC. 
Clinically, duration and anatomic extent of colonic inflammation are the most important risk 
factors for CRC in chronic ulcerative colitis. Chronic inflammation increases oxidative stress; 
promotes repeated cycles of injury, regeneration, and repair; and accelerates the 
accumulation of oncogenic mutations. Over time, accumulation of these mutations may 
result in dysplasia, an unequivocal neoplastic change in the colon. With additional key 
mutations, dysplasia can transform into invasive colorectal cancer.(93) Other established risk 
factors include primary sclerosing cholangitis (PSC) (increases the relative risk of CRC 4.8-
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fold compared with just chronic ulcerative colitis alone) and a family history of CRC 
(increases the risk of CRC 2.5-9.2 fold compared with chronic ulcerative colitis alone). (94) 
Other risk factors such as backwash ileitis and young age at diagnosis (in some studies) 
have been described; however, the clinical role of these factors remains to be determined. (95) 
Smoking reduces the risk of CRC in chronic ulcerative colitis by 50%, but increases the risk 
of CRC in Crohn's disease 4-fold. (96) Pseudopolyps also increase the risk of CRC in chronic 
ulcerative colitis, by 2.5-fold, perhaps either as a historical marker of more severe 
inflammation or because pseudopolyps may obscure the sensitivity of surveillance 
colonoscopy. (97) 
The ultimate protective factor against the development of CRC in chronic ulcerative colitis is 
proctocolectomy for all patients, beginning 8-10 years after the onset of disease. The 
currently recommended strategy for preventing CRC in this setting is to perform regular 
surveillance colonoscopy in all patients beginning at 8-10 years after the onset of disease, 
with proctocolectomy reserved for those patients with histologic evidence of dysplasia on 
mucosal biopsies. A colectomy at the time of low-grade dysplasia detection would have 
prevented advanced neoplasia from developing. (98) 
22. Chemoprevention 
5-ASA agents; have been suggested to have chemopreventive properties because of their 
structural and partial functional relationship with aspirin. A 2005 meta-analysis of 9 
observational studies identified a significant risk reduction associated with 5-ASA therapy, 
with the OR for dysplasia and colorectal cancer combined (ie, combined endpoint) at 51% in 
patients with ulcerative colitis. Although the existing evidence for the protective association 
between 5-ASA use and colorectal cancer or dysplasia is promising but inconclusive, the 
potential benefit is based on good clinical rationale, and given the excellent safety profile of 
this class of drugs, will likely encourage compliance with long-term prescribed therapy. (99) 
Steroids, aspirin, NSAIDs. There are several studies that suggest steroids, aspirin, and 
NSAIDs may reduce the risk of CRC in chronic ulcerative colitis. Although the long-term 
use of these therapies is not routinely encouraged in this patient population, these data are 
helpful in suggesting that a common anti-inflammatory or anticancer mechanism shared 
with 5-ASA may be important. (100) 
Immunomodulators; data regarding the effects of these agents on CRC risk are mixed. The 
reason for these observed differences may relate to differences in the molecular properties of 
immunomodulators compared with other anti-inflammatory therapies, differences in the 
reduction in inflammation or mucosal healing achieved with each medication, or differences 
in the neoplasia risk of the underlying population taking each medication. (101) 
Ursodeoxycholic acid. The strongest for chemoprevention is for ursodeoxycholic acid in 
PSC-chronic ulcerative colitis patients reducing the risk of CRC by 80%. Ursodeoxycholic 
acid is an antioxidant that reduces the colonic concentration of the secondary bile acid 
deoxycholic acid, a carcinogen. (102)  
Folate. In the setting of sporadic CRC, low folate levels have been associated with an 
increased risk of developing colorectal adenomas and carcinomas. Patients with IBD are at 
risk for low folate levels due to reduced intestinal absorption because of competitive 
inhibition from sulfasalazine use and because of folate loss due to active disease. Several 
case-control studies show a nonstatistical trend that patients with chronic ulcerative colitis 
who consume folate tend to have a reduced risk of CRC. Despite lack of definitive clinical 
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evidence, many experts recommend folate supplementation in patients with long-standing 
chronic ulcerative colitis, on the basis of biological rationale and safety. (103,104) 
 
5-ASA Formulation Clinical 
Response 
Induction 
Remission 
Maintenance 
Remission 
Mucosal 
Healing 
Delayed and sustained release + + + + 
Delayed release + - + - 
Olsalazine - - + - 
Balsalazide + - - - 
Table 1. Proven efficacy of 5-ASA therapy in patients with ulcerative colitis 
23. Pregnancy with ulcerative colitis 
Fertility is affected in postsurgical ulcerative colitis. There are no increases in adverse 
outcomes with quiescent ulcerative colitis. Active disease at conception increases the risk for 
adverse outcomes. The majority of medications for ulcerative colitis are safe in pregnancy 
and breastfeeding as shown in table 2 and table 3. (105-109) 
 
Category B Medications Category C, D Medications Contraindicated 
Oral, topical mesalamine Corticosteroids Methotrexate 
Sulfasalazine, olsalazine, 
balsalazide 
Azathioprine Thalidomide 
Infliximab 6- mercaptopurine   
Ciprofloxacin, metronidazole 
(after first trimester) 
Cyclosporine   
Loperamide Diphenoxylate + atropine   
Table 2. Safety of IBD Medications During Pregnancy 
 
Safe to Use When Indicated Limited No Data Contraindicated 
Oral, topical mesalamine Infliximab Methotrexate 
Sulfasalazine, olsalazine, balsalazide Azathioprine Thalidomide 
Low doses of steroids (< 20 mg) 6- mercaptopurine Cyclosporine 
Table 3. Safety of IBD Medications During Breastfeeding 
The indications for surgery during pregnancy are identical to those for nonpregnant 
patients, including obstruction, perforation, abscess, and hemorrhage. Although the 
obstetric indications for caesarean section do not differ in women with IBD, women with 
IBD undergo elective caesarean sections more frequently than do women in the normal 
population. (110)  
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24. Quality of living for patients with ulcerative colitis 
Ulcerative colitis negatively affects physical and psychosocial well-being. Quality of Living 
is diminished in many patients with ulcerative colitis; strategies for improvement of Quality 
of Living must therefore be included in any therapeutic plan and there must be a 
multifaceted approach to improve Quality of Living. (111) 
Disease activity seems to be the principal factor affecting Quality of Living. Identifying other 
potential factors that have a negative impact on Quality of Living is vital in order to achieve 
therapeutic success. Although drug therapy for ulcerative colitis is effective in achieving and 
maintaining remission, medication nonadherence remains a considerable obstacle, 
especially in quiescent disease. Patient-physician communication is crucial for successful 
management of patients with ulcerative colitis. Ultimately, choosing a therapy that is 
convenient, effective, and safe will help improve adherence, maintain remission, and 
potentially decrease the need for surgery or development of colorectal cancer. (112,113) 
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